Article information
Resumen
La Digestive Disease Week siempre ofrece novedades interesantes. Respecto de la enfermedad por reflujo gastroesofágico (ERGE), los estudios de este año enfatizan el papel del aumento de peso y de los factores psicológicos tanto en la génesis de los síntomas como en la falta de respuesta al tratamiento. Respecto del esófago de Barrett, se consolida la ablación mediante radiofrecuencia como tratamiento de elección para los casos asociados a displasia o neoplasia in situ. Finalmente, respecto de la esofagitis eosinofílica destacan los estudios que muestran hasta que punto es difícil diferenciar entre esofagitis eosinofílica y ERGE. Por otro lado, los esteroides tópicos y las dietas de exclusión se perfilan como 2 alternativas terapéuticas efectivas.
Palabras clave:
Enfermedad por reflujo gastroesofágico
Abstract
Interesting advances are always reported in Digestive Disease Week. This year's studies on gastroesophageal reflux disease (GERD) stressed the role of weight gain and psychological factors in both symptom production and lack of treatment response. In Barrett's esophagus, radiofrequency ablation has become the treatment of choice in cases associated with dysplasia or neoplasms in situ. Finally, notable studies of eosinophilic esophagitis highlighted the difficulty of distinguishing between this entity and GERD. Topical steroids and exclusion diets are effective therapeutic alternatives.
Keywords:
Gastroesophageal reflux disease
Full text is only aviable in PDF
Bibliografía
[1.]
K. Blondeau, C. Caenepeel, V. Boecxstaens, S. Depeyper, L. Holvoet, G.E. Boeckxstaens, et al.
Determinants of Symptom Perception During Impedance-pH Monitoring: Do Psychosocial Factors and ‘Somatization’ Play a Role?.
Gastroenterology, 140 (2011), pp. S246
[2.]
L. Van Oudenhove, C. Caenepeel, V. Boecxstaens, S. Depeyper, L. Holvoet, G.E. Boeckxstaens, J.E. Tack, et al.
Associations between patient characteristics and GERD symptoms: are psychosocial factors and ‘somatization’ more important than reflux parameters?.
Gastroenterology, 140 (2011), pp. S298-S299
[3.]
E. Rey, M. Barcelo, A. Varez-Sanchez, M. Az-Rubio.
Factors associated with the onset of GERD at 5 years: a longitudinal study.
Gastroenterology, 140 (2011), pp. S620
[4.]
J.C. Wu, A.D. Mak, Y.W. Chan, A. Tsang, J.J. Sung, F.K.L. Chan, et al.
Gastroesophageal reflux disease (GERD) is strongly associated with psychological disorders in the general population: a community-based study.
Gastroenterology, 140 (2011), pp. S725
[5.]
M. Singh, N. Gupta, J. Lee, S. Gaddam, B.K. Smith, D.K. Sullivan, et al.
Temporal effects of weight change on gastroesophageal reflux disease (GERD) in obese subjects: a large prospective study.
Gastroenterology, 140 (2011), pp. S189-S190
[6.]
P. Bytzer, H. Mattsson, B. Wernersson.
Partial symptom response to proton pump inhibitors in patients with non-erosive reflux disease and reflux esophagitis.
Gastroenterology, 140 (2011), pp. S583
[7.]
D. Stamler, R. Fass, M.F. Vaezi, P. Sharma, A. Bian, K. Valentine, F.J. Huff.
Clinical characteristics of GERD patients who incompletely responded to PPI therapy.
Gastroenterology, 140 (2011), pp. S583
[8.]
F. Zerbib, K. Belhocine, M. Simon, M. Capdepont, J.P. Galmiche, S.B. Des Varannes.
Inadequate response to PPIs in GERD: a prospective study of associated factors using 24-hour esophageal phimpedance monitoring off therapy.
Gastroenterology, 140 (2011), pp. S579
[9.]
R. Dickman, M. Boaz, S. Aizic, R. Gingold-Belfer, A.I. Sperber, R. Fass, et al.
Comparison of anxiety and depression in gastroesophageal reflux disease (GERD) patients who failed proton pump inhibitor (PPI) therapy versus those who fully responded to it.
Gastroenterology, 140 (2011), pp. S582
[10.]
P.B. Miner, D.G. Silberg, M. Ruth, F. Miller, J.E. Pandolfino.
Doseresponse effect of lesogaberan, a novel gamma-aminobutyric acid type B (GABAB) receptor agonist, on reflux episodes in patients with gastroesophageal reflux disease with symptoms despite proton pump inhibitor treatment.
Gastroenterology, 140 (2011), pp. S578
[11.]
N.J. Shaheen, H. Denison, K. Bjorck, M. Karlsson, D.G. Silberg.
Efficacy of a novel gamma-aminobutyric acid type B receptor (GABA B) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to ppi therapy.
Gastroenterology, 140 (2011), pp. S580
[12.]
D.O. Castell, F. Zerbib, S.B. Des Varannes, J.P. Galmiche, M.F. Vaezi, C. Keywood.
Efficacy and tolerability of ADX10059, a mGluR5 negative allosteric modulator, as add on therapy to proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD).
Gastroenterology, 140 (2011), pp. S577
[13.]
T. Hershcovici, L.K. Jha, R. Gadam, O.Z. Fass, C. Wendel, T. Navarro-Rodriguez, et al.
Comparison of therapeutic strategies for patients with refractory gastroesophageal reflux disease (GERD)-A randomized, double blind, placebo-controlled trial.
Gastroenterology, 140 (2011), pp. S579
[14.]
S.J. Kang, K.S. Hong, J.P. Im, J.S. Kim.
Are proton pump inhibitors a true risk factor of hip and spine fractures? A longitudinal cohort study.
Gastroenterology, 140 (2011), pp. S724
[15.]
M. Mello, R. Weideman, B.L. Cryer, B. Little, G. Brown.
Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients.
Gastroenterology, 140 (2011), pp. S732
[16.]
H. Khalili, E.S. Huang, B.C. Jacobson, C.A. Camargo, D. Feskanich, A.T. Chan.
Chronic proton pump inhibitor (PPI) use and risk of HIP fracture: results from the nurses’ health study.
Gastroenterology, 140 (2011), pp. S134-S135
[17.]
S. Ngamruengphong, G.I. Leontiadis, S. Radhi, K. Nugent.
Use of proton pump inhibitors and fracture: meta-analysis of observational studies.
Gastroenterology, 140 (2011), pp. S731
[18.]
W.K. Lo, K.L. Obstein, W.W. Chan.
Proton pump inhibitor use and the risk of bone fracture: a meta-analysis.
Gastroenterology, 140 (2011), pp. S582
[19.]
K.K. Tsoi, S.C. Ng, M.C. Wong, H.W. Hirai, T. Lam, F.K.L. Chan.
Current use of proton pump inhibitors is associated with an increased risk of osteoporotic fractures: a meta-analysis.
Gastroenterology, 140 (2011), pp. S210
[20.]
R. Laheij, P. De Jager, E. Gemen, M.G. Van Oijen, R. Van Gageldonk-Lafeber, P.D. Siersema, et al.
Gastric acid suppressive therapy and community-acquired pneumonia, etiology and outcome.
Gastroenterology, 140 (2011), pp. S391
[21.]
K.S. Hong, S.J. Kang, J.P. Im, J.S. Kim.
Are proton pump inhibitors a true risk factor in clostridium difficile infection? A longitudinal cohort study.
Gastroenterology, 140 (2011), pp. S79
[22.]
A. Gupta, B.M. Attar, R. Agarwal.
Proton pump inhibitors and the risk of clostridium difficile associated diarrhea: a systematic review and meta-analysis.
Gastroenterology, 140 (2011), pp. S210
[23.]
J.J. Focks, M.G. Van Oijen, A. Lanas, F. Verheugt, M.A. Brouwer.
Coadministration of proton pump inhibitors and clopidogrel: a systematic review on laboratory and clinical endpoints.
Gastroenterology, 140 (2011), pp. S395
[24.]
J.T. Gau, R. Chen, T.C. Kao.
Hypomagnesaemia and uses of proton pump inhibitors.
Gastroenterology, 140 (2011), pp. S80
[25.]
M. Nakamura, T. Arisawa, T. Shibata, T. Tahara, M. Okubo, H. Shiroeda, et al.
Prospective study of collagenous colitis onset associated with long-term administration of proton pump inhibitors.
Gastrointestinal Endoscopy, 73 (2011), pp. AB290
[26.]
S. Gaddam, P.E. Young, B.R. Alsop, N. Gupta, H. Gavini, A.D. Higbee, et al.
Relationship between barrett's esophagus (BE) length and the risk of high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with non dysplastic barrett's esophagus results from a large multicenter cohort.
Gastroenterology, 140 (2011), pp. S81
[27.]
T.K. Desai, K. Krishnan, N.R. Samala, J.D. Cluley, C.W. Howden.
Metaanalysis of the risk of esophageal adenocarcinoma in non-dysplastic Barrett's esophagus.
Gastroenterology, 140 (2011), pp. S223
[28.]
A. Amin, N.R. Samala, T.K. Desai.
The incidence of esophageal adenocarcinoma in barrett's esophagus (BE) low grade dysphasia (LGD) is 1 to 1.9% annually and may be a fraction of nonesophageal mortality: a meta-analysis of 40 studies.
Gastroenterology, 140 (2011), pp. S223
[29.]
L. Alvarez-Herrero, W.L. Curvers, F.G. Van Vilsteren, B. Weusten, J.J. Bergman.
Prague C & M Classification in Barrett's esophagus: is it really reliable in daily practice?.
Gastrointestinal Endoscopy, 73 (2011), pp. AB114
[30.]
P. Sharma, J. Dent, D. Armstrong, J.J.G.H. Bergman, L. Gossner, Y. Hoshihara, et al.
The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C & M Criteria.
Gastroenterology, 131 (2006), pp. 1392-1399
[31.]
Y.C. Lee, M.B. Cook, S. Bhatia, W.H. Chow, E.M. El-Omar, H. Goto, et al.
Interobserver reliability in the endoscopic diagnosis and grading of Barrett's esophagus: an Asian multinational study.
Endoscopy, 42 (2010), pp. 699-704
[32.]
C.Y. Chang, Y.C. Lee, C.T. Lee, C.H. Tu, J.C. Hwang, H. Chiang, et al.
The application of prague C and M criteria in the diagnosis of Barrett's esophagus in an ethnic chinese population.
Am J Gastroenterol, 104 (2009), pp. 13-20
[33.]
R.A. Ganz, J.I. Allen, G.H. Leon.
Barrett's esophagus is over-diagnosed in clinical practice: results of the Barrett's esophagus endoscopic reversal (BEER) study.
Gastrointestinal Endoscopy, 73 (2011), pp. AB113
[34.]
S.B. Wani, J.R. Goldblum, J. Post, S. Gaddam, N. Gupta, B.R. Alsop, et al.
Agreement among expert gastrointestinal pathologists for low-grade dysplasia (LGD) in Barrett's esophagus (BE) and implications for progression: results from a large, multicenter cohort study.
Gastroenterology, 140 (2011), pp. S80
[35.]
R.E. Verbeek, M.G. Van Oijen, F.J. Ten Kate, F.P. Vleggaar, M.E. Schipper, J.W. Van Baal, et al.
Risk factors for prevalent adenocarcinomas in patients with high-grade dysplasia in Barrett's esophagus: a dutch population-based study.
Gastroenterology, 140 (2011), pp. S667
[36.]
A. Bu-Sneineh, W. Tam, M. Schoeman, R. Fraser, A.R. Ruszkiewicz, E. Smith, et al.
The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus.
Alimentary Pharmacology & Therapeutics, 32 (2010), pp. 1023-1030
[37.]
N. De Bortoli, I. Martinucci, P. Piaggi, S. Maltinti, G. Bianchi, E. Ciancia, et al.
Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
Alimentary Pharmacology & Therapeutics, 33 (2011), pp. 1019-1027
[38.]
S.J. Spechler, P. Sharma, R.F. Souza, J.M. Inadomi, N.J. Shaheen.
American Gastroenterological Association technical review on the management of Barrett's esophagus.
Gastroenterology, 140 (2011), pp. E18-E52
[39.]
F. Kastelein, M. Spaander, K. Biermann, E.W. Steyerberg, H. Geldof, P. Ter Borg, et al.
Proton pump inhibitors and the risk of neoplastic progression in Barrett's esophagus: results of a large multicenter prospective cohort study.
Gastroenterology, 140 (2011), pp. S218
[40.]
J.A. Jankowski, N.B. Vakil, M.K. Ferguson, C. Bennett, P. Moayyedi, J.J. Bergman, et al.
Barrett's dysplasia cancer task force-bad cat: a global, multidisciplinary, consensus on the management of high grade dysplasia and early mucosal cancer in Barrett's esophagus.
Gastroenterology, 140 (2011), pp. S178
[41.]
R.E. Pouw, K. Wirths, P. Eisendrath, C.M. Sondermeijer, F.J. Ten Kate, P. Fockens, et al.
Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia.
Clin Gastroenterol Hepatol, 8 (2010), pp. 23-29
[42.]
N.J. Shaheen, P. Sharma, B.F. Overholt, H.C. Wolfsen, R.E. Sampliner, K.K. Wang, et al.
Radiofrequency ablation in Barrett's esophagus with dysplasia.
New Engl J Med, 360 (2009), pp. 2277-2288
[43.]
C.S. Jayasekera, R. Cade, R. Chen, R. Williams, F. Macrae, P. Desmond, et al.
Endoscopic mucosal resection is essential for optimal treatment of invasive dysplastic Barrett's oesophagus prior to halo ablation program.
Gastrointestinal Endoscopy, 73 (2011), pp. AB283-AB284
[44.]
H. Manner, O. Pech, A. May, J. Pohl, C. Ell.
Outcomes of endoscopic therapy in a large cohort of patients with Barrett's early cancer with “low-risk” submucosal invasion.
Gastrointestinal Endoscopy, 73 (2011), pp. AB197
[45.]
J.M. Tian, L.S. Lutzke, G.A. Prasad, J.T. Lewis, E.C. Gorospe, K.K. Wang.
Esophagectomy does not improve survival for esophageal adenocarcinoma patients who have submucosal lesions on endoscopic mucosal resection.
Gastroenterology, 140 (2011), pp. S80-S81
[46.]
H. Manner, T. Rabenstein, K. Braun, O. Pech, A. May, J. Pohl, et al.
Final results of a prospective randomized trial on thermal ablation of Barrett's mucosa with concomitant esomeprazole treatment versus surveillance plus PPI in patients cured from early Barrett's cancer by endoscopic resection (APE Study) Hendrik Manner, Thomas Rabenstein, Kirsten Braun, Oliver Pech, Andrea May, Juergen Pohl, Christian Ell.
Gastrointestinal Endoscopy, 73 (2011), pp. AB197
[47.]
O. Pech, A. May, H. Manner, J. Pohl, C. Ell.
Endoscopic resection in 953 patients with mucosal Barrett's cancer.
Gastrointestinal Endoscopy, 73 (2011), pp. AB146
[48.]
R.J. Haidry, J.U. Dunn, S. Thorpe, G. Fullarton, H. Smart, P. Bhandari, et al.
Radio frequency ablation is more effective in shorter segments of Barrett's oesophagus for eradication of high grade dysplasia/intramucosal cancer-Results from the UK RFA HALO Registry.
Gastroenterology, 140 (2011), pp. S215
[49.]
W.J. Bulsiewicz, S. Pasricha, E.S. Dellon, R.D. Madanick, M. Spacek, R.C. Orlando, et al.
Efficacy and predictors of structure development following radiofrequency ablation for Barrett's esophagus at a tertiary referral center.
Gastroenterology, 140 (2011), pp. S217
[50.]
K.Y.N. Phoa, F.G. Van Vilsteren, C.M. Sondermeijer, L. Alvarez-Herrero, F.J. Ten Kate, M. Visser, et al.
Endoscopic resection for Barrett's esophagus with high-grade dysplasia and/orearly cancer: durability of the post-treatment neosquamous epithelium at 5-year follow-up.
Gastrointestinal Endoscopy, 73 (2011), pp. AB198
[51.]
N.J. O’Farrell, N. Ravi, J.O. Larkin, G. Wilson, C. Muldoon, J.V. Reynolds, et al.
Early oesophageal cancer: changing treatment trends in an Upper GI (Gastrointestinal) tertiary referral centre over the past decade (2000–2010).
Irish J Med Sci, 180 (2011), pp. S115
[52.]
N.J. Shaheen, K.K. Wang, H.C. Wolfsen, D.E. Fleischer, B.E. Overholt, J.A. Galanko, et al.
Durability of reversion to neosquamous epithelium follow radiofrequency ablation for dysplastic be: longterm follow-up of the AIM dysplasia trial.
Gastroenterology, 140 (2011), pp. S179
[53.]
G.A. Prasad, K.T. Dunagan, J.M. Tian, L. Cadman, K.K. Wang, L.S. Lutzke, et al.
Recurrence of intestinal metaplasia following radiofrequency ablation: rates and predictors.
Gastroenterology, 140 (2011), pp. 718
[54.]
J. Akiyama, J. Vassalle, S.N. Marcus, G. Triadafilopoulos.
Effective acid suppression is important in squamous reepithelialization after radiofrequency ablation of barrett's esophagus.
Gastroenterology, 140 (2011), pp. S179
[55.]
S.K. Ratuapli, M.D. Crowell, K.C. Ruff, H.J. Kim, V.K. Sharma, R. Pannala, et al.
Radiofrequency ablation achieves ninety six percent complete response for intestinal metaplasia (CR-IM) in Barrett's esophagus: a single center experience.
Gastrointestinal Endoscopy, 73 (2011), pp. AB209
[56.]
S.K. Ratuapli, M.D. Crowell, K.C. Ruff, H.J. Kim, V.K. Sharma, R. Pannala, et al.
Factors associated with achieving complete response-intestinal metaplasia (CR-IM) with a single radiofrequency ablation session.
Gastrointestinal Endoscopy, 73 (2011), pp. AB276
[57.]
W.J. Bulsiewicz, S. Pasricha, E.S. Dellon, R.D. Madanick, N.J. Shaheen.
The effect of operator experience on treatment of dysplastic Barrett's esophagus with radiofrequency ablation.
Gastroenterology, 140 (2011), pp. S211
[58.]
N. Moy, M.G. Heckman, N. Gonsalves, S.R. Achem, I. Hirano.
Interobserver agreement on endoscopic esophageal findings in eosinophilic esophagitis (EoE).
Gastroenterology, 140 (2011), pp. S236
[59.]
D.L. Francis, A.S. Arora, K.L. Jensen, S. Linker-Nord, A.E. Foxx-Orenstein.
The Role of GERD in eosinophilic esophagitis.
Gastroenterology, 140 (2011), pp. S235-S236
[60.]
E. Toto, C.P. Garrean, A.V. Hayman, N. Gonsalves, I. Hirano.
Differentiation of GERD from eosinophilic esophagitis (EoE): predictive factors and response to PPI trial.
Gastroenterology, 140 (2011), pp. S237-S238
[61.]
K. Ravi, T.C. Smyrk, D.A. Katzka, J.A. Alexander, A.E. Foxx-Orenstein, D.L. Francis.
Predictive value of histologic features to distinguish the presence of pathologic esophageal acid exposure in patients with dense esophageal eosinophilic infiltration.
Gastroenterology, 140 (2011), pp. S240
[62.]
R. Lamba, M.B. Feuling, M.B. Levy, R.J. Noel.
Allergy testing in pediatric eosinophilic esophagitis. Identification of IgE and delayed hypersensitivity food reactions and its impact on management.
Gastroenterology, 140 (2011), pp. S243
[63.]
N. Gonsalves, B. Doerfier, I. Hirano.
Long term maintenance therapy with dietary restriction in adults with eosinophilic esophagitis.
Gastroenterology, 140 (2011), pp. S180-S181
[64.]
K. Peterson, F. Clayton, L.A. Vinson, J.C. Fang, K.K. Boynton, G.J. Gleich, et al.
Utility of an elemental diet in adult eosinophilic esophagitis.
Gastroenterology, 140 (2011), pp. S180
[65.]
S.K. Gupta, M.H. Collins, J.D. Lewis, R.H. Farber.
Efficacy and safety of oral budesonide suspension (OBS) in pediatric subjects with eosinophilic esophagitis (EoE): results from the double-blind, placebo-controlled PEER Study.
Gastroenterology, 140 (2011), pp. S179
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
